NCT03453034View on ClinicalTrials.gov

Tolerance and Pharmacokinetics of TQ-B3233

PHASE1UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 22, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Tumor
Interventions
DRUG

TQ-B3233

QD or BID in different stage of this research

Trial Locations (1)

100142

RECRUITING

Beijing cancer hospital, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY